1
|
Sasikumar PG, Ramachandra M. Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development. Front Immunol 2022; 13:752065. [PMID: 35585982 PMCID: PMC9108255 DOI: 10.3389/fimmu.2022.752065] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Accepted: 03/29/2022] [Indexed: 12/20/2022] Open
Abstract
Pioneering success of antibodies targeting immune checkpoints such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has changed the outlook of cancer therapy. Although these antibodies show impressive durable clinical activity, low response rates and immune-related adverse events are becoming increasingly evident in antibody-based approaches. For further strides in cancer immunotherapy, novel treatment strategies including combination therapies and alternate therapeutic modalities are highly warranted. Towards this discovery and development of small molecule, checkpoint inhibitors are actively being pursued, and the efforts have culminated in the ongoing clinical testing of orally bioavailable checkpoint inhibitors. This review focuses on the small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy and highlights various chemotypes/scaffolds and their characterization including binding and functionality along with reported mechanism of action. The learnings from the ongoing small molecule clinical trials and crucial points to be considered for their clinical development are also discussed.
Collapse
|
2
|
Sasikumar PG, Sudarshan NS, Adurthi S, Ramachandra RK, Samiulla DS, Lakshminarasimhan A, Ramanathan A, Chandrasekhar T, Dhudashiya AA, Talapati SR, Gowda N, Palakolanu S, Mani J, Srinivasrao B, Joseph D, Kumar N, Nair R, Atreya HS, Gowda N, Ramachandra M. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Commun Biol 2021; 4:699. [PMID: 34103659 PMCID: PMC8187357 DOI: 10.1038/s42003-021-02191-1] [Citation(s) in RCA: 74] [Impact Index Per Article: 24.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 05/05/2021] [Indexed: 12/17/2022] Open
Abstract
Small molecule immune checkpoint inhibitors targeting PD-1 and other pathways may offer advantages including ease of dosing, ability to manage immune-related adverse events (irAEs) due to their shorter pharmacokinetic exposure and opportunity to target more than one pathway for improving efficacy. Here we describe the identification and characterization of CA-170, an amino acid inspired small molecule inhibitor of PD-L1 and VISTA derived from the interface of PD-1 and PD-L1. CA-170 exhibited potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes. Observed blocking of PD-L1 signaling and binding to PD-L1 in the cellular context without preventing the assembly of PD-1:PD-L1 complex support the formation of a defective ternary complex as the mechanism of action of CA-170. Oral administration of CA-170 resulted in increased proliferation and activation of T cells in the tumor, and significant anti-tumor efficacy in a number of immunocompetent mouse tumor models either as a single agent or in combination with approved therapeutics. These results prompted the advancement of CA-170 to human clinical trials.
Collapse
Affiliation(s)
| | | | - Srinivas Adurthi
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | | | | | | | | | | | - Amit A Dhudashiya
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | | | - Nagesh Gowda
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | | | - Jiju Mani
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | - Bandi Srinivasrao
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | - David Joseph
- NMR Research Centre, Indian Institute of Science, Bangalore, Karnataka, India
| | - Nigam Kumar
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | - Rashmi Nair
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | - Hanudatta S Atreya
- NMR Research Centre, Indian Institute of Science, Bangalore, Karnataka, India
| | - Nagaraj Gowda
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | | |
Collapse
|
3
|
Sasikumar PG, Ramachandra RK, Adurthi S, Dhudashiya AA, Vadlamani S, Vemula K, Vunnum S, Satyam LK, Samiulla DS, Subbarao K, Nair R, Shrimali R, Gowda N, Ramachandra M. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther 2019; 18:1081-1091. [PMID: 31015307 DOI: 10.1158/1535-7163.mct-18-0737] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Revised: 10/26/2018] [Accepted: 04/15/2019] [Indexed: 11/16/2022]
Abstract
Pioneering success of antibodies targeting immune checkpoints such as PD-1 and CTLA4 has opened novel avenues for cancer immunotherapy. Along with impressive clinical activity, severe immune-related adverse events (irAE) due to the breaking of immune self-tolerance are becoming increasingly evident in antibody-based approaches. As a strategy to better manage severe adverse effects, we set out to discover an antagonist targeting PD-1 signaling pathway with a shorter pharmacokinetic profile. Herein, we describe a peptide antagonist NP-12 that displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. In preclinical models of melanoma, colon cancer, and kidney cancers, NP-12 showed significant efficacy comparable with commercially available PD-1-targeting antibodies in inhibiting primary tumor growth and metastasis. Interestingly, antitumor activity of NP-12 in a preestablished CT26 model correlated well with pharmacodynamic effects as indicated by intratumoral recruitment of CD4 and CD8 T cells, and a reduction in PD-1+ T cells (both CD4 and CD8) in tumor and blood. In addition, NP-12 also showed additive antitumor activity in preestablished tumor models when combined with tumor vaccination or a chemotherapeutic agent such as cyclophosphamide known to induce "immunologic cell death." In summary, NP-12 is the first rationally designed peptide therapeutic targeting PD-1 signaling pathways exhibiting immune activation, excellent antitumor activity, and potential for better management of irAEs.
Collapse
Affiliation(s)
| | | | - Srinivas Adurthi
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | - Amit A Dhudashiya
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | | | | | | | - Leena K Satyam
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | | | | | - Rashmi Nair
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | - Rajeev Shrimali
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | - Nagaraj Gowda
- Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India
| | | |
Collapse
|